Cancer is a major societal, public health and economic challenge, with more than 20 million new cases and nearly 9.7 million deaths in 2022. The incidence of cancer is expected to increase due to lifestyle changes and a rapidly ageing population.

 

There is a need for cancer biomarkers that can be used at different stages of patient management, including early detection, prognosis, prediction of treatment response and monitoring of disease progression.

 

The DxPG80.Lab test, which has been validated in rigorous clinical studies, can support decisions throughout the patient care pathway.